As one of the leading pediatric BMT programs in the country, we perform among the largest volumes of autologous and allogeneic transplants. In addition to treating malignant diseases, we are proficient in treating a variety of nonmalignant diseases through BMT, such as bone marrow failure syndromes, hemoglobinopathies, metabolic disorders, immune deficiencies, and histiocytic and hemophagocytic disorders. We are also proud members of the Pediatric Blood and Marrow Transplant Consortium (PBMTC). Our team has:
-
One of the largest pediatric BMT programs in the country, performing 88 BMTs in 2018.
-
Been recognized as a national leader in transplanting patients with sickle cell disease, curing more than 73 children.
-
100-plus-day survival rates, better than the national average for autologous and allogeneic transplants.
-
An average of more than 70 BMTs annually over the past three years and more than 1,000 BMTs since our program’s inception in 1985.
-
Been recognized for performing the world’s first successful, unrelated cord blood transplant for a patient with sickle cell disease.
-
A growing unique, multidisciplinary Immunohematology Program focused on curing immunodeficiencies and immune dysregulation through BMT.
-
Status as one of a select group of centers offering gene therapy for patients with sickle cell disease.
-
Been serving as the leader of more than 40 institutions nationwide on the Sickle Cell Transplant to Prevent Disease Exacerbation (STRIDE) Study, investigating the role of BMT in providing safe and effective cures for young adults with sickle cell disease.
Our BMT team:
-
Shanmuganathan Chandrakasan, MD
-
Lisa Daley-Bauer, PhD
-
Ann Haight, MD
-
Edwin Horwitz, MD, PhD
-
Lakshmanan Krishnamurti, MD
-
Kathryn Leung, MD, FAAP, Clinical Director
-
Muna Qayed, MD, MSCR
-
Kirsten Williams, MD